Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.

Clinical lymphoma & myeloma

Volumn 9, Issue 4, 2009, Pages 302-306

  Dimopoulos, Meletios A ^a   Roussou, Maria ^a   Gavriatopoulou, Maria ^a   Zagouri, Flora ^a   Migkou, Magdalini ^a   Matsouka, Charis ^a   Barbarousi, Despina ^a   Christoulas, Dimitrios ^a   Primenou, Erasmia ^a   Grapsa, Irini ^a   Terpos, Evangelos ^a   Kastritis, Efstathios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; DEXAMETHASONE; PYRAZINE DERIVATIVE; THALIDOMIDE;

ADULT; AGED; ARTICLE; DRUG ADMINISTRATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; PREDICTION AND FORECASTING; RECURRENT DISEASE; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PREDICTIVE VALUE OF TESTS; PYRAZINES; RECURRENCE; RENAL INSUFFICIENCY; RISK FACTORS; SURVIVAL RATE; THALIDOMIDE; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 77449137146     PISSN: None     EISSN: 19380712     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.059     Document Type: Article

References (0)